Cost Analysis in Helicobacter pylori Eradication Therapy Based on a Database of Health Insurance Claims in Japan.
Kengo TokunagaChihiro SuzukiMiyuki HasegawaIkuo FujimoriPublished in: ClinicoEconomics and outcomes research : CEOR (2021)
High success rate of first-line eradication contributes to saving in total eradication costs by reducing costs of subsequent therapy, irrespective of patients' smoking status or BMI class. The combination of more potent acid-inhibitory medicine and low-dose CAM may be the optimal regimen in terms of efficacy and cost-benefit in Japan.
Keyphrases
- health insurance
- helicobacter pylori
- helicobacter pylori infection
- low dose
- end stage renal disease
- affordable care act
- chronic kidney disease
- newly diagnosed
- ejection fraction
- body mass index
- high dose
- prognostic factors
- peritoneal dialysis
- emergency department
- smoking cessation
- bone marrow
- adverse drug
- weight loss
- replacement therapy